



- **Name:** Jeong-Yeol Park
- **Current Position:** Department of Obstetrics and Gynecology,
College of Medicine, University of Ulsan, Asan Medical Center,
- **Country:** Korea
- **Educational Background:**
 - 1989-1995 M.D. from Gyeongsang University Medical College, Korea
 - 1997-2000 Master from Ulsan University Medical College, Korea
 - 2002-2009 PhD from Ulsan University Medical College, Korea
- **Professional Experience:**
 - 1999-2000 Internship at College of Medicine,
University of Ulsan, Asan Medical Center, Seoul, Korea
 - 2000-2004 Residency at Department of Obstetrics and Gynecology,
College of Medicine, University of Ulsan, Asan Medical Center,
Seoul, Korea
 - 2004-2007 Public Health Care Doctor at Division of Gynecologic Oncology,
Department of Obstetrics and Gynecology, Center for Uterine Cancer,
National Cancer Center, Research Institute and Hospital, Korea
 - 2007-2009 Clinical fellowship at Department of Obstetrics and Gynecology,
College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea
 - 2009-Present Clinical associate professor at Department of Obstetrics and Gynecology,
College of Medicine, University of Ulsan, Asan Medical Center
- **Professional Organizations:**
 - 2016 Gynecologic Oncology Group
 - 2016 Principal Editor of Journal of Gynecologic Oncology
 - 2016 Secretariat General of Korean Society of Gynecologic Oncology
 - 2018 Secretariat General of Korean Society of Gynecologic Endoscopy and Minimally Invasive Surgery
 - 2019 Secretariat General of Korean Society of Obstetrics and Gynecology
- **Main Scientific Publications:**
 - 1) An Open-label Multicenter Randomized, Phase III Study for Advanced Relapsed Ovarian Cancer
 - 2) A Double-blind, Randomized, Multicenter, Placebo controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist
 - 3) A phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety
 - 4) Single-arm and Open, Clinical Pharmacology I, II and Therapeutic Exploratory Study

to Assess the Efficacy and the Safety of Combination regimen in Patients with Recurrent or Refractory Ovarian Cancer.

- 5) A randomized, parallel group, open-label, active controlled, multicenter Phase III trial in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer.
- 6) Many GOG studies; GOG 213, 218, 233, 258 etc